• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jmedgeneJournal of Medical GeneticsCurrent TOCInstructions for authors
J Med Genet. Jul 2000; 37(7): 489–497.
PMCID: PMC1734633

A clinical study of 57 children with fetal anticonvulsant syndromes


BACKGROUND—Anticonvulsants taken in pregnancy are associated with an increased risk of malformations and developmental delay in the children. To evaluate the pattern of abnormalities associated with prenatal anticonvulsant exposure further, we undertook a clinical study of 57 children with fetal anticonvulsant syndromes.
METHODS—Fifty two children were ascertained through the Fetal Anticonvulsant Syndrome Association and five were referred to the Aberdeen Medical Genetics Service. Pregnancy and medical history were obtained through a standardised questionnaire and interview and the children were examined.
RESULTS—Thirty four (60%) were exposed in utero to valproate alone, four (7%) to carbamazepine alone, four (7%) to phenytoin alone, and 15 (26%) to more than one anticonvulsant. Forty six (81%) reported behavioural problems, 22 (39%) with hyperactivity or poor concentration of whom four (7%) had a diagnosis of attention deficit and hyperactivity disorder. Thirty four (60%) reported two or more autistic features, of whom four had a diagnosis of autism and two of Asperger's syndrome. Forty four (77%) had learning difficulties, 46 (81%) had speech delay, 34 (60%) had gross motor delay, and 24 (42%) had fine motor delay. Nineteen (33%) had glue ear and 40 (70%) had joint laxity involving all sizes of joints. Of 46 who had formal ophthalmic evaluation, 16 (34%) had myopia.
CONCLUSIONS—Speech delay, joint laxity, glue ear, and myopia are common in the fetal anticonvulsant syndromes and autistic features and hyperactivity form part of the behavioural phenotype.

Keywords: fetal anticonvulsant syndrome; fetal valproate syndrome; teratogen; birth defects

Full Text

The Full Text of this article is available as a PDF (215K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Eller DP, Patterson CA, Webb GW. Maternal and fetal implications of anticonvulsive therapy during pregnancy. Obstet Gynecol Clin North Am. 1997 Sep;24(3):523–534. [PubMed]
  • Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology. 1992 Apr;42(4 Suppl 5):149–160. [PubMed]
  • Kelly TE. Teratogenicity of anticonvulsant drugs. I: Review of the literature. Am J Med Genet. 1984 Nov;19(3):413–434. [PubMed]
  • Meadow R. Anticonvulsants in pregnancy. Arch Dis Child. 1991 Jan;66(1 Spec No):62–65. [PMC free article] [PubMed]
  • Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet. 1995 Sep;32(9):724–727. [PMC free article] [PubMed]
  • Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy. 1997 May-Jun;17(3):561–564. [PubMed]
  • Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner HA, Gladstone R, Ashby P, Weksberg R, Einarson T, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA. 1994 Mar 9;271(10):767–770. [PubMed]
  • DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. The fetal valproate syndrome. Am J Med Genet. 1984 Nov;19(3):473–481. [PubMed]
  • Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr. 1975 Aug;87(2):285–290. [PubMed]
  • Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med. 1989 Jun 22;320(25):1661–1666. [PubMed]
  • Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet. 1997 Jan 10;68(1):18–24. [PubMed]
  • Vestermark V, Vestermark S. Teratogenic effect of carbamazepine. Arch Dis Child. 1991 May;66(5):641–642. [PMC free article] [PubMed]
  • Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, Flannery DB, Pellock JM, Harrod MJ, Lammer EJ, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet. 1988 Jan;29(1):171–185. [PubMed]
  • Winter RM, Donnai D, Burn J, Tucker SM. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet. 1987 Nov;24(11):692–695. [PMC free article] [PubMed]
  • Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child. 1993 Sep;69(3 Spec No):288–291. [PMC free article] [PubMed]
  • Omtzigt JG, Los FJ, Hagenaars AM, Stewart PA, Sachs ES, Lindhout D. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat Diagn. 1992 Nov;12(11):893–897. [PubMed]
  • Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, Stewart PA, Gaillard HL, Sachs ES, Wladimiroff JW, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology. 1992 Apr;42(4 Suppl 5):119–125. [PubMed]
  • Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 1991 Mar 7;324(10):674–677. [PubMed]
  • Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis. 1973 Sep;32(5):413–418. [PMC free article] [PubMed]
  • Dean JC, Moore SJ, Osborne A, Howe J, Turnpenny PD. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet. 1999 Sep;56(3):216–220. [PubMed]
  • Lindhout D, Meinardi H, Meijer JW, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology. 1992 Apr;42(4 Suppl 5):94–110. [PubMed]
  • Battino D, Binelli S, Caccamo ML, Canevini MP, Canger R, Como ML, Croci D, De Giambattista M, Granata T, Pardi G, et al. Malformations in offspring of 305 epileptic women: a prospective study. Acta Neurol Scand. 1992 Mar;85(3):204–207. [PubMed]
  • Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child. 1996 Dec;75(6):517–520. [PMC free article] [PubMed]
  • Whitmore K, Bax MC. Checking the health of school entrants. Arch Dis Child. 1990 Mar;65(3):320–326. [PMC free article] [PubMed]
  • Lindhout D, Höppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia. 1984 Feb;25(1):77–83. [PubMed]
  • Hoyt CS, Billson FA. Maternal anticonvulsants and optic nerve hypoplasia. Br J Ophthalmol. 1978 Jan;62(1):3–6. [PMC free article] [PubMed]
  • Sutcliffe AG, Jones RB, Woodruff G. Eye malformations associated with treatment with carbamazepine during pregnancy. Ophthalmic Genet. 1998 Jun;19(2):59–62. [PubMed]
  • Astley SJ, Clarren SK. A case definition and photographic screening tool for the facial phenotype of fetal alcohol syndrome. J Pediatr. 1996 Jul;129(1):33–41. [PubMed]
  • Autti-Rämö I, Gaily E, Granström ML. Dysmorphic features in offspring of alcoholic mothers. Arch Dis Child. 1992 Jun;67(6):712–716. [PMC free article] [PubMed]
  • Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 1999 Feb;33(2-3):145–158. [PubMed]
  • Koch S, Jäger-Roman E, Lösche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr. 1996 Jun;85(6):739–746. [PubMed]
  • Hanson JW, Myrianthopoulos NC, Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr. 1976 Oct;89(4):662–668. [PubMed]
  • Shapiro S, Hartz SC, Siskind V, Mitchell AA, Slone D, Rosenberg L, Monson RR, Heinonen OP. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet. 1976 Feb 7;1(7954):272–275. [PubMed]
  • Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology. 1982 Nov;32(11):1247–1254. [PubMed]
  • Gaily E, Kantola-Sorsa E, Granström ML. Intelligence of children of epileptic mothers. J Pediatr. 1988 Oct;113(4):677–684. [PubMed]
  • Gaily E, Kantola-Sorsa E, Granström ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol. 1990 May;32(5):403–414. [PubMed]
  • Bennett GD, Lau F, Calvin JA, Finnell RH. Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation. Epilepsia. 1997 Apr;38(4):415–423. [PubMed]
  • Christianson AL, Chesler N, Kromberg JG. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol. 1994 Apr;36(4):361–369. [PubMed]
  • Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Dev Med Child Neurol. 1997 Sep;39(9):632–634. [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...